drugset / Trial / NCT04638426
Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups of HL237 tablets and the control group.
Timeline
- Start
- 2020-09-10
- Primary completion
- 2021-05
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HL237 | Unknown | 100 mg | — |
| Subject | HL237 | Unknown | 200 mg | — |
| Subject | HL237 | Unknown | 400 mg | — |